Arthritis Cure

🔥+ Arthritis Cure 05 Jun 2020 Find out about psoriatic arthritis, including the symptoms and when to get ... as remission) and periods when they get worse (known as flare-ups or relapses).

Arthritis Cure COVID-19 ANNOUNCEMENT We have canceled our elective (nonurgent) cases as per the Governor's Executive Order however we are ...

The new PubMed site will become the default in mid-May. Click here to try it now! Frequently asked questions

Result Filters

Format

Send to

Choose Destination

Arthritis Curehow to Arthritis Cure for

  • 1 selected item: 30031494

Fetching bibliography...

Generate a file for use with external citation management software.

Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005.

Author information

1
Department of Paediatrics, Division of Rheumatology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
2
Department of Paediatrics, Division of Rheumatology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. Electronic address: [email protected]

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is a distinctive subtype of juvenile idiopathic arthritis, characterized by fever and arthritis, often accompanied by rash, sometimes by generalized lymphadenopathy, hepatosplenomegaly, and serositis. The diagnosis requires adequate exclusion of infectious, oncologic, autoimmune, and autoinflammatory diseases. Macrophage activation syndrome, a serious and potentially fatal complication of sJIA, requires prompt evaluation and treatment. Newer biologic agents, particularly interleukin-1 and interleukin-6 inhibitors, are highly effective and have transformed the treatment approach by reducing the use of systemic glucocorticoids. Primary care providers have a crucial role in monitoring children with sJIA for disease-related complications and medication-related for 1 last update 2020/06/05 adverse events.Systemic juvenile idiopathic arthritis (sJIA) is a distinctive subtype of juvenile idiopathic arthritis, characterized by fever and arthritis, often accompanied by rash, sometimes by generalized lymphadenopathy, hepatosplenomegaly, and serositis. The diagnosis requires adequate exclusion of infectious, oncologic, autoimmune, and autoinflammatory diseases. Macrophage activation syndrome, a serious and potentially fatal complication of sJIA, requires prompt evaluation and treatment. Newer biologic agents, particularly interleukin-1 and interleukin-6 inhibitors, are highly effective and have transformed the treatment approach by reducing the use of systemic glucocorticoids. Primary care providers have a crucial role in monitoring children with sJIA for disease-related complications and medication-related adverse events.

Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Arthritis Curehow to Arthritis Cure for Juvenile idiopathic arthritis; Macrophage activation syndrome; Pediatrics; Rheumatology; Systemic juvenile idiopathic arthritis

PMID:
30031494
DOI:
10.1016/j.pcl.2018.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

You are here: NCBI > Literature > PubMed
Support Center
External link. Please review our privacy policy.